Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Law

Showing results (141-150 of 341) with videos related to

Pageof 35
Sort By:
The Journal of Pediatrics|June 14, 2017
Attrition and Mortality of Children Receiving Antiretroviral Treatment through the Universal Coverage Health Program in ThailandSirinya Teeraananchai, Stephen J Kerr, Thanyawee Puthanakit, et al.
Annals of Tropical Medicine and Parasitology|April 1, 1989
Hepatitis A in Mauritius: an apparent transition from endemic to epidemic transmission patternsF E Shaw, S C Hadler, J E Maynard, et al.
Journal of Hepatology|May 11, 2006
Cancer incidence in people with hepatitis B or C infection: a large community-based linkage studyJanaki Amin, Gregory J Dore, Dianne L O'Connell, et al.
AIDS (London, England)|September 16, 2009
AIDS-related and non-AIDS-related mortality in the Asia-Pacific region in the era of combination antiretroviral treatmentKathleen Falster, Jun Yong Choi, Basil Donovan, et al.
Carcinogenesis|May 1, 1991
Susceptibility to phenobarbital promotion of hepatotumorigenesis: correlation with differential expression and induction of hepatic drug metabolizing enzymes in heavy and light male (C3H x VY) F1 hybrid miceG L Wolff, J E Leakey, J J Bazare, et al.
The Journal of Clinical Investigation|July 1, 1978
Regulation of blood flow to the aortic media in dogsD D Heistad, M L Marcus, E G Law, et al.
Plos One|June 27, 2014
Moving away from Ritonavir, Abacavir, Tenofovir, and Efavirenz (RATE)--agents that concern prescribers and patients: a feasibility study and call for a trialAmit C Achhra, Mark A Boyd, Matthew G Law, et al.
Epidemiology and Infection|May 19, 2006
Potential biases in estimates of hepatitis C RNA clearance in newly acquired hepatitis C infection among a cohort of injecting drug usersJ Amin, M G Law, J Micallef, et al.
BMC Infectious Diseases|August 13, 2015
Antiretroviral treatment use, co-morbidities and clinical outcomes among Aboriginal participants in the Australian HIV Observational Database (AHOD)David J Templeton, Stephen T Wright, Hamish McManus, et al.
HIV Medicine|February 26, 2015
Clinical and demographic factors associated with low viral load in early untreated HIV infection in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trialM G Law, A Achhra, S G Deeks, et al.
Pageof 35

Showing results (141-150 of 341) with videos related to

Sort By:
Pageof 35
The Journal of Pediatrics|June 14, 2017
Attrition and Mortality of Children Receiving Antiretroviral Treatment through the Universal Coverage Health Program in ThailandSirinya Teeraananchai, Stephen J Kerr, Thanyawee Puthanakit, et al.
Annals of Tropical Medicine and Parasitology|April 1, 1989
Hepatitis A in Mauritius: an apparent transition from endemic to epidemic transmission patternsF E Shaw, S C Hadler, J E Maynard, et al.
Journal of Hepatology|May 11, 2006
Cancer incidence in people with hepatitis B or C infection: a large community-based linkage studyJanaki Amin, Gregory J Dore, Dianne L O'Connell, et al.
AIDS (London, England)|September 16, 2009
AIDS-related and non-AIDS-related mortality in the Asia-Pacific region in the era of combination antiretroviral treatmentKathleen Falster, Jun Yong Choi, Basil Donovan, et al.
Carcinogenesis|May 1, 1991
Susceptibility to phenobarbital promotion of hepatotumorigenesis: correlation with differential expression and induction of hepatic drug metabolizing enzymes in heavy and light male (C3H x VY) F1 hybrid miceG L Wolff, J E Leakey, J J Bazare, et al.
The Journal of Clinical Investigation|July 1, 1978
Regulation of blood flow to the aortic media in dogsD D Heistad, M L Marcus, E G Law, et al.
Plos One|June 27, 2014
Moving away from Ritonavir, Abacavir, Tenofovir, and Efavirenz (RATE)--agents that concern prescribers and patients: a feasibility study and call for a trialAmit C Achhra, Mark A Boyd, Matthew G Law, et al.
Epidemiology and Infection|May 19, 2006
Potential biases in estimates of hepatitis C RNA clearance in newly acquired hepatitis C infection among a cohort of injecting drug usersJ Amin, M G Law, J Micallef, et al.
BMC Infectious Diseases|August 13, 2015
Antiretroviral treatment use, co-morbidities and clinical outcomes among Aboriginal participants in the Australian HIV Observational Database (AHOD)David J Templeton, Stephen T Wright, Hamish McManus, et al.
HIV Medicine|February 26, 2015
Clinical and demographic factors associated with low viral load in early untreated HIV infection in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trialM G Law, A Achhra, S G Deeks, et al.
Pageof 35